What Happened?
• On December 31, 2025, Corcept announced it received a CRL from the FDA, denying approval of Corcept’s new drug application for relacorilant as a treatment for patients with hypertension secondary to hypercortisolism.
• According to the Company’s release, the FDA acknowledged the results of the previous GRACE and GRADIENT drug trials, but “concluded it could not arrive at a favorable benefit-risk assessment for relacordilant without Corcept providing additional evidence of effectiveness”
Why it Matters:
• Today, in direct response to this news, Corcept’s stock price fell by $31.42 (44.76%) per share to open at $38.78 per share on December 31, 2025.
• This drop marks a new 52-week low for Corcept’s stock, dropping to levels not seen since September 2024.
To receive more information, please fill out the form.
